troikaa
Excellence built on basics
Innovation -- Quality -- Services
 

   

Troydecyl

Description:

Trodecyl (sodium tetradecyl sulfate injection) is a sterile nonpyrogenic solution for intravenous use as a sclerosing agent. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration.

Indication:

Troydecyl is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks.
 

Dosage & Administration:

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if precipitated or discolored. Troydecyl is for intravenous use only. The strength of solution required depends on the size and degree of varicosity. The 3% solution is preferred for larger varicosities.

The dosage should be kept small, using 0.5 to 2 ml (preferably 1 ml maximum) for each injection, and the maximum single treatment should not exceed 10 ml.

Availability:
 3% solution    2 ml  ampoules

< back

 

 

 

 
 

   

Troydoca

Description:

Troydoca (Polidocanol) is a sterile solution that is injected into varicose veins to cause closure of the affected vein.

Polidocanol has a sclerosant and local anaesthetic effect.  This permits almost painless sclerotherapy.  The effect is directed mostly at the vein intima.  While there is great affinity with damaged intima there is no effect on intact vascular linings, so a sclerosant effect occurs only on veins with actual varicose changes and not on veins with moderate cylindrical dilation.  This sclerosant effect is due to irritation of the vein intima, which causes a local, adhesive thrombosis in the area of the damaged endothelium.

 

The compression bandage applied after treatment presses the vein walls together and prevents re-canalization of the organized thrombus, so that the desired conversion of the thrombus into a fibrous scar takes place. With paravasal application of Polidocanol, the local oedema formation leads to compression of the varices and cicatricial consolidation. With appropriate selection of concentration and dosage and with correct treatment methods and aftercare (compression treatment), poidocanol can be easily tolerated and is reliable and lasting sclerosant.

Indication:

Sclerotherapy of various (branch varicosis; perforantes varicosis; operative main vein varicosis treatment combined with sclerotherapy), venectasias (spider veins), haemorrhoids, anal fissures and gaemangiomas.

Dosage & Administration:

Conventional Dosage:
Polidocanol is for strictly intravenous injection (sclerotherapy of varices) or strictly sub mucous injection (sclerotherapy of haemorrhoids). In general, a dose of 2 mg/kg body weight per day should not be exceeded.

Sclerotherapy of Varices:
The quantity of the dose and the concentration of the solution depend on the thickness of the varicose section.  The smallest varicose are treated with 0.5 – 1.0 % solution, medium-sized varicose with 1.0-2.0% solution and large varicose with 3.0-5.0% solution.  One should start with a rather weak solution and inject 0.2-0.5 ml.  If the required sclerosant effect does not occur, the concentration, not the dose, is increased. In the case of very large varices up to 2 ml may be injected.

Haemorrhoids:
 Sclerotherapy is used for internal 1st degree haemorrhoids (success rate 90%) and for 2nd degree haemorrhoids (success rate 25%). 

Dosage:
Give 0.5 – 1.5 ml polidocanol 3% per node in a strictly submocous injection. A maximum of 2 ml should be administered during the initial treatment session.  In subsequent sessions (at intervals of 1-2 weeks) a maximum of 3 ml polidocanol 3% may be administered.

Availability:
3 % solution 30mg/ml    2 ml   ampoule.

< back

 

 

 

 
 

   

Troyamine

Description:

Troyamine (Ethanolamine Oleate) Injection is a mild sclerosing agent. When injected intravenously, troyamine injection acts primarily by irritation of the intimal endothelium of the vein and produces a sterile dose-related inflammatory response. This results in fibrosis and possible occlusion of the vein. Troyamine injection also rapidly diffuses through the venous wall and produces a dose-related extravascular inflammatory reaction.

The oleic acid component of the troyamine injection is responsible for the inflammatory response, and may also activate coagulation by release of tissue factor and activation of Hageman factor.
 

Indication:

Troyamine injection is indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. Troyamine  is not indicated for the treatment of patients with esophageal varices that have not bled. There is no evidence that treatment of this population decreases the likelihood of bleeding.

Dosage & Administration:

Local Troyamine injection sclerotherapy of esophageal varices should be performed by physicians who are familiar with an acceptable technique. The usual intravenous dose is 1.5 to 5.mL per varix. The maximum dose per treatment session should not exceed 20 mL.  Submucosal injections are not recommended as they are reportedly more likely to result in ulceration at the site of injection. To obliterate the varix, injections may be made at the time of the acute bleeding episode and then after one week, six weeks, three months, and six months as indicated.

Note: Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit.

Availability:
5 % solution   5ml ampoule

< back